miltefosine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
cytostatic 1810 58066-85-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • impavido
  • miltefosine
  • hexadecylphosphocholine
  • hexadecylphosphorylcholine
  • miltefos
hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
  • Molecular weight: 407.58
  • Formula: C21H46NO4P
  • CLOGP: -2.38
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 58.59
  • ALOGS: -6.32
  • ROTB: 20

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 19, 2014 FDA KNIGHT THERAPS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC P01CX04 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
Other agents against leishmaniasis and trypanosomiasis
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
CHEBI has role CHEBI:50846 immunomodulator
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35820 antiprotozoal drug
FDA EPC N0000190851 Antileishmanial

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Visceral leishmaniasis indication 186803007 DOID:9146
Cutaneous leishmaniasis indication 240637006 DOID:9111
American mucocutaneous leishmaniasis indication 403135004
Sjogren-Larsson syndrome contraindication 111303009 DOID:14501
Pregnancy, function contraindication 289908002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.29 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
50MG IMPAVIDO KNIGHT THERAPS N204684 March 19, 2014 RX CAPSULE ORAL March 19, 2021 TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
RAC-alpha serine/threonine-protein kinase Kinase IC50 5.02 CHEMBL
Dual specificity phosphatase Cdc25A Enzyme IC50 4.60 CHEMBL

External reference:

IDSource
C0123429 UMLSCUI
D02494 KEGG_DRUG
53EY29W7EC UNII
6362 INN_ID
713676008 SNOMEDCT_US
006585 NDDF
1494066 RXNORM
25615 MMSL
d07564 MMSL
713642004 SNOMEDCT_US
4035630 VANDF
CHEMBL125 ChEMBL_ID
DB09031 DRUGBANK_ID
CHEBI:75283 CHEBI
3599 PUBCHEM_CID
C039128 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
IMPAVIDO HUMAN PRESCRIPTION DRUG LABEL 1 69051-300 CAPSULE 50 mg ORAL NDA 18 sections